Red yeast rice
Also called: RYR, red mold rice, Monascus purpureus fermented rice, red yeast rice extract
Rice fermented by a fungus, usually Monascus purpureus. Depending on strain and fermentation, it can contain monacolin K, which is chemically identical to the prescription drug lovastatin; amounts vary widely between products. It is also sold as food and in traditional Chinese medicine.
- Category
- Other
- Forms
- Fermented rice and red yeast rice extracts; monacolin K content is usually not stated on labels
- Strongest evidence
- A Strong
- Reviewed
- 2026-10-30
Class 1 Well studied in people. A 2015 meta-analysis analyzed 20 randomized studies (6,663 subjects) of red yeast rice with known monacolin K content versus placebo or an active control; 11 compared red yeast rice alone with placebo, and 2 added it to another agent (valsartan or nattokinase). [2]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
AHeart and blood vessels3 topics
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| LDL cholesterol | A | A 2015 meta-analysis of 20 randomized studies of red yeast rice with known monacolin K content found LDL cholesterol fell 1.02 mmol/L versus placebo, similar to statins; safety assessment quality was low in most studies. [2] |
| HDL cholesterol, triglycerides and apolipoproteins | C | A 2024 meta-analysis of 14 double-blind trials (2012–2022) found red yeast rice extract lowered total and LDL cholesterol but did not significantly change HDL cholesterol, triglycerides or apolipoproteins A-I and B. [3] |
| Products low in monacolin K | C | NCCIH states it is unknown whether products with very little monacolin K lower cholesterol; some products contain less monacolin K than the level known to lower cholesterol in clinical trials. [1] |
Main constituents: Monacolins, including monacolin K (structurally identical to lovastatin) [1]; Citrinin, a contaminant toxic to the kidneys, found in some products [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- LiverTox describes monacolin (lovastatin) content of 1 to 10 mg per tablet in products and cites a tolerability trial of red yeast rice at 2,400 mg twice daily. [4]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score CABCDEA: well known causeE: unlikely cause
LiverTox (last update June 4, 2018): likelihood score C, a probable rare cause of clinically apparent liver injury.
Details and sources - Pregnancy and breastfeedingNCCIH: no studies on safety during pregnancy or breastfeeding; red yeast rice products are not recommended for those who are pregnant or lactating.
1 statement in the profile.
Details and sources - Interactions with medicines2 listed
CYP3A4
Details and sources - Cancer evaluations (IARC, NTP)1 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notifications3 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- FDA (2007): red yeast rice products found to contain lovastatin are a threat to health because lovastatin can cause severe muscle problems leading to kidney impairment; the risk is greater at higher doses or with other medicines that raise the risk of muscle adverse reactions. [5]
- NCCIH: products with significant monacolin K can have the same potential side effects as statin drugs, including muscle, kidney and liver damage, and may cause digestive problems such as diarrhea, nausea and stomach pain. [1]
- LiverTox likelihood score C (probable rare cause of clinically apparent liver injury): isolated case reports, mild to moderate and self-limited; no acute liver failure or vanishing bile duct syndrome attributed to red yeast rice. [4]
- NCCIH: a 2018 EFSA opinion concluded monacolin K exposure from red yeast rice products could lead to severe side effects and could not identify a guaranteed safe dietary level, whereas a 2019 systematic review of trials suggested the products were safe. [1]
- A 2019 meta-analysis of 53 RCTs (8,535 subjects; red yeast rice alone or with other nutraceuticals) found no increased risk of musculoskeletal disorders (OR 0.94, 95% CI 0.53–1.65). [6]
- Japan, late 2023 to early 2024: kidney injury was linked to specific Beni-koji (red yeast rice) tablets. In a nationwide survey of nephrologists (192 patients), 94.1% had eGFR under 60 ml/min/1.73m2, laboratory findings showed features of Fanconi syndrome, and 87% still had eGFR under 60 at last observation. Citrinin was not produced by the implicated strains. [7]
- Researchers at Japan's National Institute of Health Sciences reported puberulic acid in the tablets that caused the outbreak (made from Monascus pilosus red yeast rice); a puberulic acid-producing fungus, Penicillium adametzioides, was found at the production factory. [8]
- Citrinin contamination: in a 2021 analysis of 37 products, only one had citrinin below the current EU maximum, and four contaminated products were labeled "citrinin-free" (as reported by NCCIH). [1]
- NCCIH: there are no studies on safety in pregnancy or breastfeeding, and red yeast rice products are not recommended for those who are pregnant or lactating. [1]
Interactions
| With | What happens |
|---|---|
| Nefazodone, certain antibiotics, antifungal and HIV drugs, other cholesterol-lowering medicines | FDA (2007): these medicines increase the risk of muscle adverse reactions with lovastatin. [5] |
| Drugs that interact with statins | NCCIH: red yeast rice products can have the same types of drug interactions as statin drugs. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- A 2017 analysis of 28 US brands cited by NCCIH found none labeled its monacolin K quantity; 2 had none detected and in the other 26 monacolin K ranged more than 60-fold, from 0.09 to 5.48 mg per 1,200 mg of red yeast rice. [1]
- NCCIH: some researchers reported that commercial lovastatin is illegally added to some red yeast rice products. [1]
Regulatory status
- US: FDA warning letters (2007) stated that red yeast rice products found to contain lovastatin "are unapproved new drugs that are marketed in violation of the Federal Food, Drug, and Cosmetic Act." Lovastatin is a prescription drug. [5]
- US: NCCIH reports that, according to FDA, red yeast rice products with enhanced or added lovastatin cannot be marketed as dietary supplements, because lovastatin was approved as a new drug before it was ever marketed as a food or dietary supplement. [1]
- US: LiverTox states that FDA has ruled red yeast rice extracts with more than trace amounts of monacolin K cannot be sold as dietary supplements, yet some products with detectable lovastatin are commercially available. [4]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Monacolin K, chemically identical to lovastatin; content varies between products Monacolins (statin identical to lovastatin) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 3 entries naming a Monascus purpureus (red yeast) fermented product (earliest NDI 836 submitted 2014-05-29; most recent NDI 1071 submitted 2018-03-23), plus 2 entries naming monacolin preparations from Monascus pilosus (NDI 46 submitted 1999-01-20; NDI 134 submitted 2001-12-28). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
- FDA (August 2007) warned consumers not to buy or eat three red yeast rice products sold online that its testing showed contained lovastatin; its warning letters called them unapproved new drugs marketed in violation of the Federal Food, Drug, and Cosmetic Act. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of red yeast rice was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P4]
- Contaminant: IARC lists citrinin in Group 3 (Volume 40 and Supplement 7, 1987). [P4]
- The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of red yeast rice or citrinin (checked 2026-10-29). [P5]
Liver (NIH LiverTox)
- LiverTox (last update June 4, 2018): likelihood score C, a probable rare cause of clinically apparent liver injury. Prospective controlled trials showed no serum enzyme elevations or clinically apparent liver injury, but isolated case reports exist; injury is probably due to lovastatin present at 1 to 10 mg per tablet. [P1]
Interactions with medicines
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- NCCIH: some researchers reported that commercial lovastatin is illegally added to some red yeast rice products; four citrinin-contaminated products in a 2021 analysis were labeled citrinin-free. [P6]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P7]
- Monacolin K (lovastatin) content — Monacolin K is chemically identical to lovastatin, FDA has called lovastatin-containing products unapproved new drugs, and content in US brands ranged from none detected to 5.48 mg per 1,200 mg, unlabeled. [P6]
- Citrinin — Citrinin is a kidney-toxic contaminant; in a 2021 analysis only 1 of 37 products was below the EU maximum. [P6]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- NCCIH: no studies on safety during pregnancy or breastfeeding; red yeast rice products are not recommended for those who are pregnant or lactating. [P6]
Sources for this profile
- NIH LiverTox. Red Yeast Rice (last update June 4, 2018), NBK548168, 2018-06-04. ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- FDA Consumer Update on red yeast rice products (date posted August 10, 2007; FDA page archived in the UNT End of Term 2008 web archive), 2007-08-10. webarchive.library.unt.edu
- IARC Monographs. List of Classifications, Volumes 1–142 (list data dated 2026-07-23; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- NCCIH (NIH). Red Yeast Rice: What You Need To Know (last updated November 2022), 2022-11. nccih.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/28/2026), 2026-10-28. ecfr.gov
Sources
- NCCIH (NIH). Red Yeast Rice: What You Need To Know (last updated November 2022), 2022-11. nccih.nih.gov
- Gerards MC, et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain: a systematic review and meta-analysis. Atherosclerosis 2015;240(2):415-23 (PMID 25897793), 2015-06. pubmed.ncbi.nlm.nih.gov
- Trogkanis E, et al. Safety and efficacy of the consumption of the nutraceutical "red yeast rice extract" for the reduction of hypercholesterolemia in humans: a systematic review and meta-analysis. Nutrients 2024;16(10) (PMID 38794691), 2024-05. pubmed.ncbi.nlm.nih.gov
- NIH LiverTox. Red Yeast Rice (last update June 4, 2018), NBK548168, 2018-06-04. ncbi.nlm.nih.gov
- FDA Consumer Update on red yeast rice products (date posted August 10, 2007; FDA page archived in the UNT End of Term 2008 web archive), 2007-08-10. webarchive.library.unt.edu
- Fogacci F, et al. Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2019;143:1-16 (PMID 30844537), 2019-05. pubmed.ncbi.nlm.nih.gov
- Shinzawa M, et al. A nationwide questionnaire study evaluated kidney injury associated with Beni-koji tablets in Japan. Kidney Int 2025;107(3):530-540 (PMID 39708997), 2025-03. pubmed.ncbi.nlm.nih.gov
- Yoshinari T, et al. (National Institute of Health Sciences, Japan). Mechanism of puberulic acid contamination in red yeast rice tablets that caused a serious food poisoning outbreak in Japan. Proc Jpn Acad Ser B Phys Biol Sci 2025;101(5):302-316 (PMID 40159186), 2025-05-09. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.